Clinical and biological predictors of ketamine response in treatment-resistant major depression: Review;Facteurs prédictifs de la réponse antidépressive à la kétamine dans les épisodes dépressifs majeurs résistants : revue de la littérature

Encephale

Volumn 43, Issue 4, 2017, Pages 354-362

  Romeo, B ^a   Choucha, W ^a   Fossati, P ^a,b   Rotge, J Y ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Ketamine; Major depressive episode; Predictors response

Indexed keywords

BIOLOGICAL FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CYANOCOBALAMIN; DEXTRO SERINE; GLUTAMIC ACID; GLUTAMINE; INTERLEUKIN 6; KETAMINE; METHIONINE; SERINE; VALINE; ANTIDEPRESSANT AGENT;

ALCOHOLISM; ANTERIOR CINGULATE; ARTICLE; CLINICAL ASSESSMENT; DEPRESSION; FAMILY HISTORY; FATTY ACID OXIDATION; GENETIC POLYMORPHISM; HUMAN; MITOCHONDRIAL RESPIRATION; NERVE CELL PLASTICITY; PREDICTIVE VALUE; PROTEIN EXPRESSION; REMISSION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; GENE EXPRESSION; GENETICS; MAJOR DEPRESSION; NEUROPSYCHOLOGICAL TEST; PROGNOSIS; PSYCHOLOGY; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; GENE EXPRESSION; HUMANS; KETAMINE; NEUROPSYCHOLOGICAL TESTS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84992709200     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2016.06.005     Document Type: Article

References (84)

1. Murrough, J.W., Charney, D.S., Is there anything really novel on the antidepressant horizon?. Curr Psychiatry Rep 14:6 (2012), 643–649.
2. Skolnick, P., Layer, R.T., Popik, P., et al. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29:1 (1996), 23–26.
3. De Maricourt, P., Jay, T., Goncalvès, P., et al. Ketamine's antidepressant effect: focus on ketamine mechanisms of action. Encéphale 40:1 (2014), 48–55.
4. Costemale-Lacoste, J.F., Guilloux, J.P., Gaillard, R., The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: a review of the literature. Encéphale 42:2 (2016), 156–164.
5. Zanos, P., Moaddel, R., Morris, P.J., et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature [Internet], 2016.
6. De Maricourt, P., Jay, T., Goncalvès, P., et al. Ketamine's antidepressant effect: literature review on clinical use. Encéphale 40:1 (2014), 15–23.
7. Berman, R.M., Cappiello, A., Anand, A., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:4 (2000), 351–354.
8. Diazgranados, N., Ibrahim, L., Brutsche, N.E., et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:8 (2010), 793–802.
9. Sos, P., Klirova, M., Novak, T., et al. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuroendocr Lett 34:4 (2013), 101–107.
10. Zarate, C.A., Brutsche, N.E., Ibrahim, L., et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71:11 (2012), 939–946.
11. Zarate, C.A. Jr., Singh, J.B., Carlson, P.J., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:8 (2006), 856–864.
12. Lapidus, K.A.B., Levitch, C.F., Perez, A.M., et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 76:12 (2014), 970–976.
13. Romeo, B., Choucha, W., Fossati, P., et al. Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Res 230:2 (2015), 682–688.
14. McGirr, A., Berlim, M.T., Bond, D.J., et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 45:4 (2015), 693–704.
15. Coyle, C.M., Laws, K.R., The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum Psychopharmacol 30:3 (2015), 152–163.
16. Carrier, N., Kabbaj, M., Sex differences in the antidepressant-like effects of ketamine. Neuropharmacology 70 (2013), 27–34.
17. Niciu, M.J., Luckenbaugh, D.A., Ionescu, D.F., et al. Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry 75:05 (2014), e417–e423.
18. Luckenbaugh, D.A., Ibrahim, L., Brutsche, N., et al. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. Bipolar Disord 14:8 (2012), 880–887.
19. Niciu, M.J., Luckenbaugh, D.A., Ionescu, D.F., et al. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. Int J Neuropsychopharmacol, 18(1), 2014 [pyu039–pyu039].
20. Phelps, L.E., Brutsche, N., Moral, J.R., et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 65:2 (2009), 181–184.
21. Schumann, G., Johann, M., Frank, J., et al. Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behavior. Arch Gen Psychiatry 65:7 (2008), 826–838.
22. Nery, F.G., Stanley, J.A., Chen, H.-H., et al. Bipolar disorder comorbid with alcoholism: a 1H magnetic resonance spectroscopy study. J Psychiatr Res 44:5 (2010), 278–285.
23. Ionescu, D.F., Luckenbaugh, D.A., Niciu, M.J., et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry 75:9 (2014), e932–e938.
24. Ionescu, D.F., Luckenbaugh, D.A., Niciu, M.J., et al. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord 17:4 (2015), 438–443.
25. Fava, M., Alpert, J.E., Carmin, C.N., et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 34:7 (2004), 1299–1308.
26. Joffe, R.T., Bagby, R.M., Levitt, A., Anxious and nonanxious depression. Am J Psychiatry 150:8 (1993), 1257–1258.
27. Davidson, J.R.T., Meoni, P., Haudiquet, V., et al. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety 16:1 (2002), 4–13.
28. Flint, A.J., Rifat, S.L., Anxious depression in elderly patients. Response to antidepressant treatment. Am J Geriatr Psychiatry 5:2 (1997), 107–115.
29. Feske, U., Frank, E., Mallinger, A.G., et al. Anxiety as a correlate of response to the acute treatment of bipolar I disorder. Am J Psychiatry 157:6 (2000), 956–962.
30. Moghaddam, B., Adams, B., Verma, A., et al. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:8 (1997), 2921–2927.
31. Murrough, J.W., Wan, L.-B., Iacoviello, B., et al. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology (Berl) 231:3 (2014), 481–488.
32. Murrough, J.W., Burdick, K.E., Levitch, C.F., et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology 40:5 (2015), 1084–1090.
33. Shiroma, P.R., Albott, C.S., Johns, B., et al. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 17:11 (2014), 1805–1813.
34. Gorlyn, M., Keilp, J.G., Grunebaum, M.F., et al. Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. J Neural Transm Vienna Austria 1996 115:8 (2008), 1213–1219.
35. Taylor, B.P., Bruder, G.E., Stewart, J.W., et al. Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am J Psychiatry 163:1 (2006), 73–78.
36. Duncan, W.C., Sarasso, S., Ferrarelli, F., et al. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol 16:02 (2013), 301–311.
37. Duncan, W.C., Selter, J., Brutsche, N., et al. Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder. J Affect Disord 145:1 (2013), 115–119.
38. Haile, C.N., Murrough, J.W., Iosifescu, D.V., et al. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 17:02 (2014), 331–336.
39. Machado-Vieira, R., Yuan, P., Brutsche, N., et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry 70:12 (2009), 1662–1666.
40. Rybakowski, J.K., Permoda-Osip, A., Skibinska, M., et al. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved?. Hum Psychopharmacol Clin Exp 28:1 (2013), 87–90.
41. Laje, G., Lally, N., Mathews, D., et al. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry 72:11 (2012), e27–e28.
42. Ortiz, R., Niciu, M.J., Lukkahati, N., et al. Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. J Affect Disord 172 (2015), 307–311.
43. Roussignol, G., Ango, F., Romorini, S., et al. Shank expression is sufficient to induce functional dendritic spine synapses in aspiny neurons. J Neurosci 25:14 (2005), 3560–3570.
44. Esser, S.K., Hill, S.L., Tononi, G., Sleep homeostasis and cortical synchronization: I. Modeling the effects of synaptic strength on sleep slow waves. Sleep 30:12 (2007), 1617–1630.
45. Ehlers, C.L., Havstad, J.W., Kupfer, D.J., Estimation of the time course of slow-wave sleep over the night in depressed patients: effects of clomipramine and clinical response. Biol Psychiatry 39:3 (1996), 171–181.
46. Kupfer, D.J., Frank, E., McEachran, A.B., et al. Delta sleep ratio. A biological correlate of early recurrence in unipolar affective disorder. Arch Gen Psychiatry 47:12 (1990), 1100–1105.
47. Argyropoulos, S.V., Hicks, J.A., Nash, J.R., et al. Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone. J Sleep Res 18:3 (2009), 342–348.
48. Nissen, C., Feige, B., König, A., et al. Delta sleep ratio as a predictor of sleep deprivation response in major depression. J Psychiatr Res 35:3 (2001), 155–163.
49. Spanier, C., Frank, E., McEachran, A.B., et al. The prophylaxis of depressive episodes in recurrent depression following discontinuation of drug therapy: integrating psychological and biological factors. Psychol Med 26:3 (1996), 461–475.
50. Liu, R.-J., Lee, F.S., Li, X.-Y., et al. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry 71:11 (2012), 996–1005.
51. Colle, R., Gressier, F., Verstuyft, C., et al. Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. J Affect Disord 175 (2015), 233–240.
52. Domschke, K., Lawford, B., Laje, G., et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol 13:1 (2010), 93–101.
53. Kim, E., Naisbitt, S., Hsueh, Y.P., et al. GKAP, a novel synaptic protein that interacts with the guanylate kinase-like domain of the PSD-95/SAP90 family of channel clustering molecules. J Cell Biol 136:3 (1997), 669–678.
54. Tu, J.C., Xiao, B., Naisbitt, S., et al. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23:3 (1999), 583–592.
55. Guilmatre, A., Huguet, G., Delorme, R., et al. The emerging role of SHANK genes in neuropsychiatric disorders. Dev Neurobiol 74:2 (2014), 113–122.
56. Nugent, A.C., Diazgranados, N., Carlson, P.J., et al. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord 16:2 (2014), 119–128.
57. Salvadore, G., Cornwell, B.R., Sambataro, F., et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35:7 (2010), 1415–1422.
58. Salvadore, G., Cornwell, B.R., Colon-Rosario, V., et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 65:4 (2009), 289–295.
59. Drevets, W.C., Savitz, J., Trimble, M., The subgenual anterior cingulate cortex in mood disorders. CNS Spectr 13:8 (2008), 663–681.
60. Rotge, J.-Y., Lemogne, C., Hinfray, S., et al. A meta-analysis of the anterior cingulate contribution to social pain. Soc Cogn Affect Neurosci 10:1 (2015), 19–27.
61. Mayberg, H.S., Targeted electrode-based modulation of neural circuits for depression. J Clin Invest 119:4 (2009), 717–725.
62. Mayberg, H.S., Brannan, S.K., Mahurin, R.K., et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 8:4 (1997), 1057–1061.
63. Wu, J., Buchsbaum, M.S., Gillin, J.C., et al. Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am J Psychiatry 156:8 (1999), 1149–1158.
64. Kito, S., Hasegawa, T., Koga, Y., Cerebral blood flow in the ventromedial prefrontal cortex correlates with treatment response to low-frequency right prefrontal repetitive transcranial magnetic stimulation in the treatment of depression. Psychiatry Clin Neurosci 66:2 (2012), 138–145.
65. Narushima, K., McCormick, L.M., Yamada, T., et al. Subgenual cingulate theta activity predicts treatment response of repetitive transcranial magnetic stimulation in participants with vascular depression. J Neuropsychiatry Clin Neurosci 22:1 (2010), 75–84.
66. Canli, T., Cooney, R.E., Goldin, P., et al. Amygdala reactivity to emotional faces predicts improvement in major depression. Neuroreport 16:12 (2005), 1267–1270.
67. Langenecker, S.A., Kennedy, S.E., Guidotti, L.M., et al. Frontal and limbic activation during inhibitory control predicts treatment response in major depressive disorder. Biol Psychiatry 62:11 (2007), 1272–1280.
68. Salvadore, G., van der Veen, J.W., Zhang, Y., et al. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol 15:08 (2012), 1063–1072.
69. Valentine, G.W., Mason, G.F., Gomez, R., et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Res Neuroimaging 191:2 (2011), 122–127.
70. Martinez-Hernandez, A., Bell, K.P., Norenberg, M.D., Glutamine synthetase: glial localization in brain. Science 195:4284 (1977), 1356–1358.
71. D'Amelio, F., Eng, L.F., Gibbs, M.A., Glutamine synthetase immunoreactivity is present in oligodendroglia of various regions of the central nervous system. Glia 3:5 (1990), 335–341.
72. Price, J.L., Drevets, W.C., Neurocircuitry of mood disorders. Neuropsychopharmacol 35:1 (2010), 192–216.
73. Yang, J., Wang, N., Yang, C., et al. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression. Biol Psychiatry 77:3 (2015), e19–e20.
74. Myint, A.M., Kim, Y.K., Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses 61:5–6 (2003), 519–525.
75. Erhardt, S., Lim, C.K., Linderholm, K.R., et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacol 38:5 (2013), 743–752.
76. Moaddel, R., Luckenbaugh, D.A., Xie, Y., et al. D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology (Berl) 232:2 (2015), 399–409.
77. Permoda-Osip, A., Dorszewska, J., Bartkowska-Sniatkowska, A., et al. Vitamin B12 level may be related to the efficacy of single ketamine infusion in bipolar depression. Pharmacopsychiatry 46:6 (2013), 227–228.
78. Villaseñor, A., Ramamoorthy, A., Silva dos Santos, M., et al. A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks: metabolomics of ketamine response in depression. Br J Pharmacol 171:8 (2014), 2230–2242.
79. Ji, Y., Hebbring, S., Zhu, H., et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 89:1 (2011), 97–104.
80. Jensen, M.D., Haymond, M.W., Rizza, R.A., et al. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 83:4 (1989), 1168–1173.
81. Tabatabaie, L., Klomp, L.W., Berger, R., et al. L-serine synthesis in the central nervous system: a review on serine deficiency disorders. Mol Genet Metab 99:3 (2010), 256–262.
82. Ebesunun, M.O., Eruvulobi, H.U., Olagunju, T., et al. Elevated plasma homocysteine in association with decreased vitamin B(12), folate, serotonin, lipids and lipoproteins in depressed patients. Afr J Psychiatry 15:1 (2012), 25–29.
83. Kate, N., Grover, S., Agarwal, M., Does B12 deficiency lead to lack of treatment response to conventional antidepressants?. Psychiatry Edgmont Pa Townsh 7:11 (2010), 42–44.
84. Murrough, J.W., Iosifescu, D.V., Chang, L.C., et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170:10 (2013), 1134–1142.